LGALS9 and plasma cell myeloma: Regarding MM specifically, studies have demonstrated the potential of protease-resistant recombinant Galectin-9 (hGal9) to inhibit the proliferation of several myeloma cell lines in vitro, including those resistant to bortezomib.